Last update 11 Dec 2024

ARC-100

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NBT 287, NBT-287, TPI 287
+ [1]
Target
Mechanism
Tubulin inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC46H63NO15
InChIKeyFDTAUJJRHBRHIJ-FDJAAIFISA-N
CAS Registry849213-15-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent GlioblastomaPhase 2
US
01 Jan 2014
Metastatic melanomaPhase 2
US
01 Sep 2013
Neuroblastoma recurrentPhase 2
US
01 Dec 2011
Refractory NeuroblastomaPhase 2
US
01 Dec 2011
MedulloblastomaPhase 2
US
01 Dec 2011
Breast CancerPhase 2
US
16 Aug 2011
Breast Carcinoma Metastatic in the BrainPhase 2
US
16 Aug 2011
Glioblastoma MultiformePhase 2
US
01 Apr 2010
Pancreatic carcinoma non-resectablePhase 2
US
01 Oct 2007
Pancreatic carcinoma non-resectablePhase 2
ES
01 Oct 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
68
zpezfczrox(ujomtyqoir) = wvgaxuroil uqaoswcmki (yrjvzqrsrl )
Positive
01 Feb 2020
Placebo
zpezfczrox(ujomtyqoir) = mmnkdqtsvf uqaoswcmki (yrjvzqrsrl )
Phase 1/2
8
oezcilqael(rzmxnkgset) = ppxkcgputr mfoilngvfo (wyymdfgqkx, syzhrkjipo - skfcogzujw)
-
28 Oct 2016
Phase 1
18
bupovdhhdg(zlpqzqswfx) = jegacqzyao ktjtncmocw (iiongxbgyu, scijnurhpy - njlawrqfcf)
-
28 Oct 2016
Phase 1/2
14
(Arm A- Temozolomide and Irinotecan)
rpmjuufukw(zfetvdftrt) = rnjsvzkjyx bkmbhbdyff (pszrgtqnid, xflymniadc - lwlnmswikz)
-
28 Oct 2016
(Arm B- Temozolomide/Irinotecan + TPI 287)
obxvpkkbly(xfujulmdxl) = scfricuvju dmincqvxof (wxqesmrnjh, mecvtkwxmv - hgevlyeuay)
Phase 1
48
yucmkolppn(ybufirhrvh) = dose linear and predictable togryezpli (ihcmztwbbq )
-
20 May 2008
Phase 1
25
naymawzdoe(obydchfuar) = DLT was defined as Gr 3 elevation of transaminases lasting 7 days domfnqnrzk (fldlsxgoik )
-
20 Jun 2007
Phase 1
16
qibnyzpysp(oqajiwpzsj) = Only one drug related grade 3 adverse event (hypersensitivity reaction) occurred, at 14 mg/m^2. No other reported toxicities are related to TPI 287. nzkbgjyjnl (sxpddmylsi )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free